

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/76561 A2

- (51) International Patent Classification⁷: **A61K 9/16**,
9/107, 38/13
- (21) International Application Number: PCT/EP01/04051
- (22) International Filing Date: 9 April 2001 (09.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0008785.8 10 April 2000 (10.04.2000) GB
- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): AMBÜHL, Michael [CH/CH]; Bahnhofstrasse 93a, CH-4313 Möhlin (CH). HAEBERLIN, Barbara [CH/CH]; Haselrain 77, CH-4125 Riehen (CH). LÜCKEL, Barbara [DE/DE]; Pestalozzistrasse 22, 79540 Lörrach (DE). MEINZER, Armin [DE/DE]; Fliederweg 2, 79426 Buggingen (DE).
- LAMBERT, Olivier [FR/FR]; Rue des Bergers 6, F-68440 Steinbrunn-le-Haut (FR). MARCHAL, Laurent [FR/FR]; 22, Rue Ernest-Bichat, F-54000 Nancy (FR).
- (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention provides a pharmaceutical composition in solid form comprising a poorly water soluble drug, a solubilizing component, and a surfactant which is semisolid or solid. The poorly soluble drug may e.g. be a cyclosporin or a macrolide.

WO 01/76561 A2

Pharmaceutical Compositions

The present invention relates to novel galenic compositions, in particular novel galenic compositions in which the active ingredient is a poorly water soluble drug e.g. a macrolide, or in particular a cyclic poly-N-methylated undecapeptide, or a cyclosporin. Cyclosporins
5 also include peptolide variants. See e.g. GB patent publications nos. 2 222 770 and 2 257 359 A and equivalents world-wide.

As discussed in the said GB patent publications, the cyclosporins present highly specific difficulties in relation to administration generally and galenic composition in particular,
10 including in particular problems of stability, drug bioavailability, and variability in inter- and intra-patient dose response .

In order to meet these and related difficulties, in GB patent publication no. 2 222 770 and 2 257 359 A, galenic compositions are disclosed comprising a cyclosporin as active ingredient
15 and which take the form of, inter alia, an emulsion, e.g. microemulsion, or emulsion, e.g. microemulsion, pre-concentrate. Such compositions typically comprise 1) a hydrophilic component, 2) a lipophilic component, and 3) a surfactant.

In accordance with the present invention it has now surprisingly been found that particularly
20 suitable galenic compositions with poorly water soluble drugs having particularly interesting bioavailability characteristics and reduced variability in inter- and intra-subject bioavailability parameters, are obtainable using a component which solubilizes the poorly water soluble drug, e.g. a lipophilic component, and a surfactant which is semisolid or solid at room temperature wherein the weight ratio of surfactant to solubilizing component is from about
25 0.3 – 4, e.g. 1 – 4, to 1. On dilution with an aqueous medium the composition forms an emulsion or microemulsion and/or particulate system.

The present invention provides in one aspect a pharmaceutical composition in solid form comprising

- 30 1) a poorly water soluble drug,
2) a solubilizing component, e.g. a lipophilic component
3) a surfactant which is semisolid or solid,

wherein the ratio of surfactant to solubilizing component, e.g. lipophilic component, is from about 0.3 – 4, e.g. 1 – 4, to 1, and which on dilution with an aqueous medium forms an emulsion or microemulsion and/or a particulate system.

5

Preferably the composition does not contain any organic hydrophilic component. Under "organic hydrophilic component" is to be understood any hydrophilic component or any hydrophilic co-component as described in the above mentioned British patent application 2 222 770, e.g. no added ethanol, propylene glycol or water, e.g. less than 0.5 % by weight of the composition organic hydrophilic component.

10

Accordingly, in one aspect the present invention provides a composition as described above which is free, e.g. substantially free, from an organic hydrophilic component.

15

In one embodiment the present invention further provides a composition which is not an emulsion, e.g. microemulsion, preconcentrate.

20

The poorly water soluble drug preferably is a lipophilic drug, e.g. a cyclosporin or a macrolide. The term "poorly water soluble", as used herein, is understood to mean a solubility in water at 20°C of less than 1, e.g. 0.01, % weight/volume, e.g. a sparingly soluble to very slightly soluble drug as described in Remington: The Science and Practice of Pharmacy, 19th Edition, Ed. A.R. Gennaro, Mack Publishing Company, US, 1995, vol. 1, p 195.

25

Suitable drugs, e.g. pharmacologically active agents, include e.g. cyclosporins and macrolides.

30

Cyclosporins to which the present invention applies are any of those having pharmaceutical utility, e.g. as immunosuppressive agents, anti-parasitic agents and agents for the reversal of multi-drug resistance, as known and described in the art, in particular Cyclosporin A (also known as Ciclosporin), Cyclosporin G, [0-(2-hydroxyethyl)-(D)Ser]⁸-Ciclosporin, and [3'-deshydroxy-3'-keto-MeBmt]¹-[Val]²-Ciclosporin. Cyclosporin A is preferred.

In one aspect the present invention provides a composition according to the present invention wherein the cyclosporine is Cyclosporin A.

5 The term "macrolide" as used herein, refers to a macrocyclic lactone, for example a compound having a 12- membered or larger lactone ring. Of particular interest are the "lactam macrolides", i.e., macrocyclic compounds having a lactam (amide) bond in the macrocycle in addition to a lactone (ester) bond, for example the lactam macrolides produced by microorganisms of the genus *Streptomyces* such as rapamycin, ascomycin, and FK-506, and their numerous derivatives and analogues. Such lactam macrolides have
10 been shown to have interesting pharmaceutical properties, particularly immunosuppressive and anti-inflammatory properties.

Rapamycin is an immunosuppressive lactam macrolide that is produced by *Streptomyces hygroscopicus*. The structure of rapamycin is given in Kessler, H., et al.; 1993; Helv. Chim. Acta; 76: 117. See, e.g., McAlpine, J.B., et al., *J. Antibiotics* (1991) 44: 688; Schreiber, S.L., et al., *J. Am. Chem. Soc.* (1991) 113: 7433; US Patent No. 3 929 992. Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its
15 very low and variable bioavailability as well as its high toxicity. Moreover, rapamycin is highly insoluble, making it difficult to formulate stable galenic compositions. Numerous derivatives of rapamycin are known. Certain 16-O-substituted rapamycins are disclosed in WO 94/02136, the contents of which are incorporated herein by reference. 40-O-substituted rapamycins are described in, e.g., in US 5 258 389 and WO 94/09010 (O-aryl and O-alkyl rapamycins); WO 92/05179 (carboxylic acid esters), US 5 118 677 (amide esters), US 5
20 118 678 (carbarnates), US 5 100 883 (fluorinated esters), US 5 151 413 (acetals), US 5 120 842 (silyl ethers), WO 93/11130 (methylene rapamycin and derivatives), WO 94/02136 (methoxy derivatives), WO 94/02385 and WO 95/14023 (alkenyl derivatives) all of which are incorporated herein by reference. 32-O-dihydro or substituted rapamycins are described, e.g., in US 5 256 790, incorporated herein by reference.

30

Rapamycin and its structurally similar analogues and derivatives are termed collectively as "rapamycins".

Ascomycins, of which FK-506 and ascomycin are the best known, comprise another class of lactam macrolides, many of which have potent immunosuppressive and anti-inflammatory activity. FK506 is a lactam macrolide immunosuppressant that is produced by Streptomyces tsukubaensis No 9993. The structure of FK506 is given in the appendix to the Merck Index,
5 11th ed. (1989) as item A5. Ascomycin is described, e.g., in US patent 3,244,592. Many derivatives of ascomycin and FK-506 have been synthesized, including halogenated derivatives such as 33-epi-chloro-33-desoxy-ascomycin described in EP 427 680. Ascomycin, FK-506 and their structurally similar analogues and derivatives are termed collectively "ascomycins".

10 The macrolide may, therefore, be rapamycin or an O-substituted derivative in which the hydroxyl group on the cyclohexyl ring of rapamycin is replaced by -OR₁ in which R₁ is hydroxyalkyl, hydroalkoxyalkyl, acylaminoalkyl and aminoalkyl; for example 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]-
15 ethyl-rapamycin and 40-O-(2-acetaminoethyl)-rapamycin.

A preferred compound is 40-O-(2-hydroxy)ethyl rapamycin as disclosed in WO 94/09010.

20 Examples of compounds of the FK 506 class are those mentioned above. They include for example FK 506, ascomycin and other naturally occurring compounds. They include also synthetic analogues.

A preferred compound of the FK 506 class is disclosed in EP 427 680, e.g. Example 66a also known as 33-epi-chloro-33-desoxy-ascomycin. Other preferred compounds are
25 disclosed in EP 465 426, and in EP 569 337, e.g. the compound of Example 71 in EP 569 337.

30 In accordance with the present invention, it has surprisingly been found that a cyclosporine or macrolide has a high solubility, e.g. a solubility of from about 20 to about 50%, in the solubilizing component, e.g. lipophilic component, of the present invention. The solubilizing component can be one of a large variety of components. A person skilled in the art can choose the appropriate solubilizing component.

The solubilizing, e.g. lipophilic component, is for example:

- i) glyceryl mono- or di fatty acid ester, e.g. of C₆-C₁₈, e.g. C₆-C₁₆, e.g. C₈-C₁₀, e.g. C₈, fatty acids, e.g. Sunfat® GDC, or acetylated derivatives thereof, e.g. Myvacet® 9-45 or 9-08, or Imwitor® 308 or 312, and/or
- ii) propylene glycol mono- or di- fatty acid ester, e.g. of C₆-C₂₀, e.g. C₈-C₁₂, fatty acids, e.g. Lauroglycol® 90, Sefsol® 218, or Capryol® 90, and/or
- iii) fatty acids or alcohols, e.g. C₆-C₂₀, saturated or mono-or di- unsaturated, e.g. oleic acid, oleyl alcohol, linoleic acid, capric acid, caprylic acid, caproic acid, tetradecanol, dodecanol, decanol, and/or
- iv) medium chain fatty acid triglycerides, e.g. C₆-C₁₂, e.g. Miglyol® 812, or long chain fatty acid triglycerides, e.g. vegetable oils, and/or
- v) mixed mono-, di-, tri-glycerides, e.g. C₆-C₂₀, e.g. C₁₆-C₁₈, e.g. Maisine®, and/or
- vi) transesterified ethoxylated vegetable oils, e.g. Labrafil® M2125 CS, and/or
- vii) esterified compounds of fatty acid and primary alcohol, e.g. C₈-C₂₀ fatty acids and C₂-C₃ alcohols, e.g. ethyl linoleate, e.g. Nikkol VF-E®, and/or
- viii) glycerol triacetate, e.g. Triacetin, and/or
- ix) triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, and/or
- x) hydrocarbons, e.g. squalene, e.g. Squalene®, Squalene Ex®, and/or
- xi) ethylene glycol esters, e.g. Monthyle®, and/or
- xii) polyglycerol fatty acid esters, e.g. diglyceryl monooleate, e.g. DGMO-C®, DGMO-90®, DGDO®, and/or
- xiii) sterols.

For example the solubility of a cyclosporin or a macrolide in Sunfat®GDC-N is about 33%, in Lauroglycol®90 about 40%, in Sefsol®218 about 50%, in oleyl alcohol more than 20%. It is to be appreciated that the solubilizing capacity may depend on the poorly water soluble drug, e.g. pharmacologically active agent, used. In general, for active agents used in dosages of from 0.25 to 100 mg per day, e.g. 0.5 to 10 mg per day, e.g. for macrolides, a solubility of from about 5 to about 10 % in the lipophilic component of the present invention may be desirable. For drugs used in dosages of from 10 to 1000 mg, e.g. 10 to 500 mg, e.g. 50 to 500 mg per day, e.g. for cyclosporins, a solubility of from about 20 to about 50 % in the lipophilic component of the present invention may be desirable.

Accordingly, the present invention provides in one aspect a composition in solid form comprising

1) a cyclosporine or macrolide

2) a solubilizing component, e.g. lipophilic component, wherein component 1) has a
5 solubility of from about 5 to about 50%

3) a surfactant which is semisolid or solid,

wherein the ratio of surfactant to solubilizing component, e.g. lipophilic component, is from
about 0.3 – 4, e.g. 1 – 4, to 1 and

10 which on dilution with an aqueous medium forms an emulsion or microemulsion and/or
particulate system.

The solubilizing component, e.g. lipophilic component, may be any one of components i) to
xiii) individually or in combination with one, two or more of the other components i) to xiii).

15 Further details for these solubilizing components, e.g. lipophilic components, are given
below.

i) Glyceryl mono- or di- C_6-C_{18} , e.g. C_6-C_{16} , fatty acid ester. Diglycerides suitable for use in
the compositions of the invention include both symmetric (i.e. α,α' -diglycerides) as well
20 as asymmetric diglycerides (i.e. α,β -diglycerides) and acetylated derivatives thereof.
They also include both uniform glycerides (in which the fatty acid constituent is
composed primarily of a single fatty acid) as well as mixed glycerides (i.e. in which the
fatty acid constituent is composed of various fatty acids) and any acetylated derivatives
thereof. The fatty acid constituent may include both saturated and unsaturated fatty
25 acids having a chain length of from C_6-C_{18} , e.g. C_6-C_{16} , e.g. C_8-C_{10} , e.g. C_8 . Particularly
suitable is caprylic diglyceride which is commercially available, e.g. under the trade
name Sunfat® GDC-N, e.g. from Taiyo Kagaku Co., Ltd. Sunfat® GDC-N has an acid
value of about 0.3, a diglyceride content of about 78.8%, and a monoester content of
about 8.9%.

30

Glyceryl mono C_6-C_{18} , e.g. C_6-C_{14} , fatty acid ester may be obtainable by esterification of
glycerol with vegetable oil followed by molecular distillation. Monoglycerides suitable for
use in the compositions of the invention include both symmetric (i.e. β -monoglycerides)

as well as asymmetric monoglycerides (α -monoglycerides) and acetylated derivatives thereof, which may be commercially available, e.g. under the trade name Myvacet®. They also include both uniform glycerides (in which the fatty acid constituent is composed primarily of a single fatty acid) as well as mixed glycerides (i.e. in which the fatty acid constituent is composed of various fatty acids) and any acetylated derivatives thereof. The fatty acid constituent may include both saturated and unsaturated fatty acids having a chain length of from e.g. C_8 - C_{10} . Particularly suitable are caprylic or capric acid monoglycerides which are commercially available, e.g. under the trade names Imwitor® 308 or Imwitor® 310, respectively, from e.g. Condea. For example Imwitor® 308 comprises at least 80 % monoglycerides and exhibits the following additional characterising data: free glycerol max 6 %, acid value max. 3, saponification value 245-265, iodine value max. 1, water content max. 1 %. Typically it comprises 1 % free glycerol, 90 % monoglycerides, 7 % diglycerides, 1 % triglycerides (H. Fiedler, "Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete", Editio Cantor Verlag Aulendorf, Aulendorf, 4th revised and expanded edition (1996), vol 1, page 798).

ii) Propylene glycol mono- or di- C_8 - C_{20} fatty acid ester. The fatty acid constituent may include both saturated and unsaturated fatty acids having a chain length of from e.g. C_8 - C_{12} . Particularly suitable are propylene glycol mono ester of caprylic and lauric acid as commercially available, e.g. under the trade names Sefsol® 218, Capryol®90 or Lauroglycol®90, from e.g. Nikko Chemicals Co., Ltd. or Gattefossé. For example Lauroglycol®90 exhibits the following additional characterising data: acid value max. 8, saponification value 200-220, iodine value max. 5, free propylene glycol content max. 5%, monoester content min. 90%; Sefsol® 218 exhibits the following additional characterising data: acid value max. 5, hydroxy value 220-280 (H. Fiedler, loc cit, vol 2, page 906, manufacturer information).

iii) Fatty acids and/or alcohols. Fatty acids may be obtainable by hydrolysis of various animal and vegetable fats or oils, such as olive oil, followed by separation of the liquid acids. The fatty acid/alcohol constituent may include both saturated and mono- or di-unsaturated fatty acids/alcohols having a chain length of from e.g. C_8 - C_{20} . Particularly suitable are, e.g. oleic acid, oleyl alcohol, linoleic acid, capric acid, caprylic acid, caproic acid, tetradecanol, dodecanol, or decanol. For example oleyl alcohol is

commercially available under the trade mark HD-Eutanol® V from e.g. Henkel KGaA. Oleyl alcohol exhibits the following additional characterising data: acid value max 0.1, hydroxy value of about 210, iodine value of about 95, saponification value max 1, D.²⁰ about 0,849, n_D²⁰ 1,462, molecular weight 268, viscosity (20°) about 35 mPa s (manufacturer information). Oleic acid exhibits the following additional characterising data: molecular weight 282,47, D.²⁰ 0,895, n_D²⁰ 1,45823, acid value 195-202, iodine value 85-95, viscosity (25°) 26 mPa s (H. Fiedler, loc cit, vol 2, page 1112; "Handbook of Pharmaceutical Excipients", 2nd Edition, Editors A. Wade and P. J. Weller (1994), Joint publication of American Pharmaceutical Association, Washington, USA and The Pharmaceutical Press, London, England, page 325).

- iv) As the medium chain fatty acid triglyceride in the lipophilic component a triglyceride of saturated fatty acid having 6 to 12, e.g. 8 to 10, carbon atoms can be used. Suitable medium chain fatty acid triglycerides are those known and commercially available under the trade names Acomed®, Myritol®, Captex®, Neobee® M 5 F, Miglyol® 810, Miglyol® 812, Miglyol® 818, Mazol®, Sefsol® 860, Sefsol® 870; Miglyol® 812 being the most preferred. Miglyol® 812 is a fractionated coconut oil comprising caprylic-capric acid triglycerides and having a molecular weight of about 520 daltons. Fatty acid composition = C₆ max. about 3%, C₈ about 50 to 65%, C₁₀ about 30 to 45%, C₁₂ max 5%; acid value about 0.1; saponification value about 330 to 345; iodine value max 1. Miglyol® 812 is available from Condea. Neobee® M 5 F is a fractionated caprylic-capric acid triglyceride available from coconut oil; acid value max. 0.2; saponification value about 335 to 360; iodine value max 0.5, water content max. 0.15%, D.²⁰ 0,930-0,960, n_D²⁰ 1,448-1,451 (manufacturer information). Neobee® M 5 F is available from Stepan Europe.

In a further alternative aspect the lipophilic component may alternatively comprise e.g. a pharmaceutically acceptable oil, preferably with an unsaturated component such as a vegetable oil.

- v) Suitable mixed mono-, di-, tri-glycerides are those known and commercially available under the trade name Maisine® from Gattefossé. They are transesterification products of corn oil and glycerol. Such products are comprised predominantly of linoleic and oleic acid mono-, di- and tri-glycerides together with minor amounts of palmitic and

stearic acid mono-, di- and tri-glycerides (corn oil itself being comprised of ca. 56% by weight linoleic acid, 30% oleic acid, ca. 10% palmitic and ca. 3% stearic acid constituents). Physical characteristics are: free glycerol max 10%, monoglycerides ca. 40%, diglycerides ca. 40%, triglycerides ca. 10%, free oleic acid content ca. 1%. Further physical characteristics are: acid value max. 2, iodine value of 85-105, saponification value of 150-175, mineral acid content = 0. The fatty acid content for Maisine® is typically: palmitic acid ca. 11%, stearic acid ca. 2.5%, oleic acid ca. 29%, linoleic acid ca. 56%, others ca. 1.5% (H. Fiedler, loc cit, vol 2, page 958; manufacturer information).

- vi) The solubilizing component may alternatively comprise suitable transesterified ethoxylated vegetable oils such as those obtained by reacting various natural vegetable oils (for example, maize oil, kernel oil, almond oil, ground nut oil, olive oil, soybean oil, sunflower oil, safflower oil and palm oil, or mixtures thereof) with polyethylene glycols that have an average molecular weight of from 200 to 800, in the presence of an appropriate catalyst. These procedures are known and an example is described in US Patent 3 288 824. Transesterified ethoxylated corn oil is particularly preferred.

Transesterified ethoxylated vegetable oils are known and are commercially available under the trade name Labrafil® (H. Fiedler, loc cit, vol 2, page 880). Examples are Labrafil® M 2125 CS (obtained from corn oil and having an acid value of less than about 2, a saponification value of 155 to 175, an HLB value of 3 to 4, and an iodine value of 90 to 110), and Labrafil® M 1944 CS (obtained from kernel oil and having an acid value of about 2, a saponification value of 145 to 175 and an iodine value of 60 to 90). Labrafil® M 2130 CS (which is a transesterification product of a C₁₂₋₁₈ glyceride and polyethylene glycol and which has a melting point of about 35 to 40°C, an acid value of less than about 2, a saponification value of 185 to 200 and an iodine value of less than about 3) may also be used. The preferred transesterified ethoxylated vegetable oil is Labrafil® M 2125 CS which can be obtained, for example, from Gattefossé, Saint-Priest Cedex, France.

- vii) As another lipophilic component esterified compounds of fatty acid and primary alcohol may be used. They may include esterified compounds of fatty acid having 8 to 20

carbon atoms and primary alcohol having 2 to 3 carbon atoms, for example, isopropyl myristate, isopropyl palmitate, ethyl linoleate, ethyl oleate, etc., with an esterified compound of linoleic acid and ethanol being particularly preferable.

- 5 viii) Glycerol triacetate or (1,2,3)-triacetin. It may be obtainable by esterification of glycerin with acetic anhydride. Glycerol triacetate is commercially available as, e.g. Priacetin® 1580 from Unichema International, or as *Eastman Triacetin* from Eastman, or from Courtaulds Chemicals Ltd. Glycerol triacetate exhibits the following additional characterising data: molecular weight 218,03, D.^{20,3} 1,159-1,163, n_D²⁰ 1,430-1,434, 10 water content max. 0.2 %, viscosity (25°) 17.4 mPa s, acid value max. 0.1, saponification value of about 766-774, triacetin content 97% min. (H. Fiedler, loc cit, vol 2, page 1580; Handbook of Pharmaceutical Excipients, loc. cit, page 534, manufacturer information).
- 15 ix) Triethyl citrate or acetyl triethyl citrate. They may be obtainable by esterification of citric acid and ethanol or esterification of citric acid and ethanol, followed by acetylation with acetic anhydride, respectively. Triethyl citrate or acetyl triethyl citrate are commercially available, e.g. under the trade names Citroflex® 2 or Citroflex® A-2, or triethyl citrate in a pharmaceutical grade under the name TEC-PG/N, from e.g. Morflex Inc. Particularly 20 suitable is triethyl citrate which has molecular weight of 276,3, a specific gravity of 1,135-1,139, a refractive index of 1,439-1,441, a viscosity (25°) of 35,2 mPa s, assay (anhydrous basis) 99,0-100,5 %, water max. 0,25 % (Fiedler, H. P., loc.cit, , vol 1, page 371; "Handbook of Pharmaceutical Excipients", loc. cit, page 540).
- 25 x) Hydrocarbons, e.g. squalene, available from e.g. Nikko Chemicals Co., Ltd.
- xi) Ethylene glycol esters, e.g. Monthyle®, available from e.g. Gattefossé.
- 30 xii) Polyglycerol fatty acid esters, with e.g. from 2 to 20, e.g. 10 glycerol units. The fatty acid constituent may include both saturated and unsaturated fatty acids having a chain length of from e.g. C₈-C₁₈. Particularly suitable is e.g. diglyceryl monooleate (DGMO), as known and commercially available from e.g. Nikko Chemicals Co., Ltd.

xiii) Sterols and derivatives thereof, for example cholesterol and derivatives thereof, in particular phytosterols, e.g. products comprising sitosterol, campesterol or stigmasterol, and ethylene oxide adducts thereof, for example soya sterols and derivatives thereof, e.g. polyethylene glycol sterols, e.g. polyethylene glycol phytosterols or polyethylene glycol soya sterols. The polyethylene glycols may have e.g. from 10 to 40 [CH₂-CH₂-O] units, e.g. 25 or 30 units. Particularly suitable is polyethylene glycol (30) phytosterol which is commercially available, e.g. under the trade name Nikkol BPS®-30, e.g. from Nikko Chemicals Co., Ltd. Further suitable is polyethylene glycol (25) soya sterol which is commercially available, e.g. under the trade name Generol® 122 E 25, e.g. from Henkel (H. Fiedler, loc cit, vol. 1, p. 680).

Although any pharmaceutically acceptable components selected from the group specified above may be used in the composition of the invention, certain components are preferred. These include oleyl alcohol, Lauroglycol®90, Sefsol® 218, Capryol®90 or Sunfat® GDC-N.

Accordingly, the present invention provides in one aspect a composition according to the present invention, wherein the solubilizing component, e.g. lipophilic component, is selected from the group consisting of

- (i) glyceryl di C₆-C₁₆ fatty acid ester,
- (ii) propylene glycol mono C₆-C₁₂ fatty acid ester,
- (iii) fatty acids and alcohols.

In the pharmaceutical composition of the present invention, in a further alternative aspect the constitutional ratio of the solubilizing component, e.g. lipophilic component, : cyclosporin may be from about 15 to 1 : 1 and preferably from about 10 to 1.5 : 1, on the basis of weight.

The term "semisolid or solid", as used herein, is understood to mean a surfactant having a melting point of e.g. above 30°C to about 40°C (semisolid) or above 40°C (solid), respectively.

Examples of suitable surfactants for use in this invention are:

- i) Reaction products of a natural or hydrogenated castor oil and ethylene oxide. The natural or hydrogenated castor oil may be reacted with ethylene oxide in a molar ratio of from about 1:35 to about 1:60, with optional removal of the polyethyleneglycol component from the products. Various such surfactants are commercially available. The polyethyleneglycol-hydrogenated castor oils available under the trade name Cremophor® are especially suitable. Particularly suitable are Cremophor® RH 40, which has a saponification value of about 50 to 60, an acid value less than about 1, a water content (Fischer) less than about 2%, an n_D^{60} of about 1.453 to 1.457 and an HLB of about 14 to 16; and Cremophor® RH 60, which has a saponification value of about 40 to 50, an acid value less than about 1, an iodine value of less than about 1, a water content (Fischer) of about 4.5 to 5.5%, an n_D^{60} of about 1.453 to 1.457 and an HLB of about 15 to 17. An especially preferred product of this class is Cremophor® RH40.
- Similar or identical products which may also be used are available under the trade names Nikkol® (e.g. Nikkol® HCO-40 and HCO-60), Mapeg® (e.g. Mapeg® CO-40h), Incrocas® (e.g. Incrocas® 40), Tagat® (for example polyoxyethylene-glycerol-fatty acid esters e.g. Tagat® RH 40) and Simulsol OL-50 (PEG-40 castor oil, having a saponification value of about 55 to 65, an acid value of max. 2, an iodine value of 25 to 35, a water content of max. 8%, and an HLB of about 13, available from Seppic). These surfactants are further described in Fiedler loc. cit..
- ii) Polyoxyethylene fatty acid esters, for example polyoxyethylene stearic acid esters of the type known and commercially available under the trade name Myrj® from ICI (Fiedler, loc. cit., 2, p. 1042). An especially preferred product of this class is Myrj® 52 having a D^{25} of about 1.1., a melting point of about 40 to 44°C, an HLB value of about 16.9., an acid value of about 0 to 1 and a saponification no. of about 25 to 35.
- iii) Polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, poloxamers, for example of the type known and commercially available under the trade names Pluronic®, Emkalyx® (Fiedler, loc. cit., 2, p. 1203). An especially preferred product of this class is Pluronic® F68 (poloxamer 188), having a melting point of about 52°C and a molecular weight of about 6800 to 8975.

- iv) Polyoxyethylene mono esters of a saturated C₁₀ to C₂₂, e.g. C₁₈ substituted e.g. hydroxy fatty acid; e.g. 12 hydroxy stearic acid PEG ester, e.g. of PEG about e.g. 600-900 e.g. 660 daltons MW, e.g. Solutol® HS 15 from BASF, Ludwigshafen, Germany.

5

- v) Polyoxyethylene alkyl ethers, e.g. polyoxyethylene glycol ethers of C₁₂ to C₁₈ alcohols, e.g. Polyoxyl 2-, 10- or 20-cetyl ether or Polyoxyl 23-lauryl ether, or polyoxyl 20-oleyl ether, or Polyoxyl 2-, 10-, 20- or 100-stearyl ether, as known and commercially available e.g. under the trade mark Brij® from ICI. An especially preferred product of this class is e.g. Brij® 35 (Polyoxyl 23 lauryl ether) or Brij® 98 (Polyoxyl 20 oleyl ether) (Fiedler, loc. cit., 1, pp. 259; Handbook of Pharmaceutical Excipients, loc. cit., page 367).

10

Similar products which may also be used are polyoxyethylene-polyoxypropylene-alkyl ethers, e.g. polyoxyethylene-polyoxypropylene- ethers of C₁₂ to C₁₈ alcohols, e.g. polyoxyethylen-20-polyoxypropylene-4-cetylether which is known and commercially available under the trade mark Nikkol PBC® 34, from e.g. Nikko Chemicals Co., Ltd. (Fiedler, loc. cit., vol. 2, pp. 1239). Polyoxypropylene fatty acid ethers, e.g. Acconon® E may also be used.

15

20

- vi) Sodium alkyl sulfates and sulfonates, and sodium alkyl aryl sulfonates, e.g. sodium lauryl sulfate, which is also known as sodium dodecyl sulfate and which is commercially available, e.g. under the trade name Texapon K12® from Henkel KGaA.

25

- vii) Water soluble tocopheryl polyethylene glycol succinic acid esters (TPGS), e.g. with a polymerisation number ca 1000, e.g. available from Eastman Fine Chemicals Kingsport, Texas, USA.

30

- viii) Alkylene polyol ether or ester. It may be suitably a C₃₋₅alkylene triol, in particular glycerol, ether or ester. Suitable C₃₋₅alkylene triol ether or ester include mixed ethers or esters, i.e. components including other ether or ester ingredients, for example transesterification products of C₃₋₅alkylene triol esters with other mono-, di- or poly-ols.

Particularly suitable alkylene polyol ether or ester are mixed C₃₋₅alkylene triol/poly-(C₂₋₄alkylene) glycol fatty acid esters, especially mixed glycerol/polyethylene- or polypropylene-glycol fatty acid esters.

5 Especially suitable alkylene polyol ether or ester for use in accordance with the present invention include products obtainable by transesterification of glycerides, e.g. triglycerides, with poly-(C₂₋₄alkylene) glycols, e.g. poly-ethylene glycols and, optionally, glycerol.

Such transesterification products are generally obtained by alcoholysis of glycerides, e.g. triglycerides, in the presence of a poly-(C₂₋₄alkylene) glycol, e.g. polyethylene glycol and, optionally, glycerol (i.e. to effect transesterification from the glyceride to the poly-alkylene glycol/glycerol component, i.e. via poly-alkylene glycolysis/glycerolysis).

10 In general such reaction is effected by reaction of the indicated components (glyceride, polyalkylene glycol and, optionally, glycerol) at elevated temperature under an inert atmosphere with continuous agitation.

15 Preferred glycerides are fatty acid triglycerides, e.g. (C₁₀₋₂₂fatty acid) triglycerides, including natural and hydrogenated oils, in particular vegetable oils. Suitable vegetable oils include, for example, olive, almond, peanut, coconut, palm, soybean and wheat germ oils and, in particular, natural or hydrogenated oils rich in (C₁₂₋₁₈fatty acid) ester residues.

20 Preferred polyalkylene glycol materials are polyethylene glycols, in particular polyethylene glycols having a molecular weight of from ca. 500 to ca. 4,000, e.g. from ca. 1,000 to ca. 2,000.

25 Suitable alkylene polyol ether or ester thus comprise mixtures of C₃₋₅alkylene triol esters, e.g. mono-, di- and tri-esters in variable relative amount, and poly (C₂₋₄alkylene) glycol mono- and di-esters, together with minor amounts of free C₃₋₅alkylene triol and free poly-(C₂₋₅alkylene) glycol. As hereinabove set forth, the preferred alkylene triol moiety is glyceryl; preferred polyalkylene glycol moieties will be polyethylene glycol, in particular having a molecular weight of from ca. 500 to ca. 4,000; and preferred fatty acid moieties will be C₁₀₋₂₂fatty acid ester residues, in particular saturated C₁₀₋₂₂fatty acid ester residues.

30 Particularly suitable alkylene polyol ether or ester may thus alternatively be defined as: transesterification products of a natural or hydrogenated vegetable oil and a polyethylene glycol and, optionally, glycerol; or compositions comprising or consisting of glyceryl mono-, di- and tri-C₁₀₋₂₂fatty acid esters and polyethylene glycol mono- and

di- C₁₀₋₂₂ fatty esters (optionally together with, e.g. minor amounts of free glycerol and free polyethylene glycol).

Preferred vegetable oils, polyethylene glycols or polyethylene glycol moieties and fatty acid moieties in relation to the above definitions are as hereinbefore set forth.

5 Particularly suitable alkylene polyol ether or ester as described above for use in the present invention are those known and commercially available under the trade name Gelucire® from e.g. Gattefossé, in particular the products

a) Gelucire® 33/01, which has an m.p. = ca. 33-38°C

10 and a saponification value = ca. 240/260;

b) Gelucire® 35/10, m.p. = ca. 29-34°C, saponification v. = ca. 120-140;

c) Gelucire® 37/02, m.p. = ca. 34-40°C, saponification v. = ca. 200-220;

d) Gelucire® 42/12, m.p. = ca. 41-46°C, saponification v. = ca. 95-115;

e) Gelucire® 44/14, m.p. = ca. 42-46°C, saponification v. = ca. 75-95;

15 f) Gelucire® 46/07, m.p. = ca. 47-52°C, saponification v. = ca. 125-145;

g) Gelucire® 48/09, m.p. = ca. 47-52°C, saponification v. = ca. 105-125;

h) Gelucire® 50/02, m.p. = ca. 48-52°C, saponification v. = ca. 180-200;

i) Gelucire® 50/13, m.p. = ca. 46-51°C, saponification v. = ca. 65-85;

j) Gelucire® 53/10, m.p. = ca. 48-53°C, saponification v. = ca. 95-115;

20 k) Gelucire® 62/05, m.p. = ca. 60-65°C, saponification v. = ca. 70-90.

Products (a) to (j) above all have an acid value of max. 2. Product (k) has an acid value max. 5. Products (b), (c) and (f) to (j) above all have an iodine value of max. 3. Product (a) has an iodine value of max. 8. Products (d) and (e) have an iodine value of max. 5 or 2. Product (k) has an iodine value of max. 10.

25 Alkylene polyol ether or ester having an iodine value of max. 2 will generally be preferred. As will be appreciated, mixtures of alkylene polyol ether or ester as defined may also be employed in the compositions of the invention.

30 Gelucire® products are inert semi-solid waxy materials with amphiphilic character. They are identified by their melting point and their HLB value. Most Gelucire® grades are saturated polyglycolised glycerides obtainable by polyglycolysis of natural hydrogenated vegetable oils with polyethylene glycols. They are composed of a mixture of

mono-, di- and tri-glycerides and mono- and di-fatty acid esters of polyethylene glycol. Particularly suitable is Gelucire® 44/14 which has a nominal melting point of 44°C and an HLB of 14. It is derived from the reaction of hydrogenated palm kernel and/or hydrogenated palm oils with polyethylene glycol 1500. It consists of approximately 20% mono-, di- and triglycerides, 72 % mono- and di- fatty acid esters of polyethylene glycol 1500 and 8% of free polyethylene glycol 1500. The fatty acid distribution for Gelucire® 44/14 is as follows: 4-10 C₈, 3-9 C₁₀, 40-50 C₁₂, 14-24 C₁₄, 4-14 C₁₆, 5-15 C₁₈. Gelucire® 44/14 exhibits the following additional characterising data: acid value of max. 2, iodine value of max. 2, saponification value of 79-93, hydroxyl value of 36-56, peroxide value of max. 6, alkalines impurities max. 80, water content max. 0.50, free glycerol content max. 3, monoglycerides content 3.0-8.0. (H. Fiedler, loc cit, vol 1, page 676; manufacturer information).

- ix) Polyethylene glycol glyceryl fatty acid ester. The fatty acid ester may include mono and/or di and/or tri fatty acid ester. The fatty acid constituent may include both saturated and unsaturated fatty acids having a chain length of from e.g. C₁₂-C₁₈. The polyethylene glycols may have e.g. from 10 to 40 [CH₂-CH₂-O] units, e.g. 15 or 30 units. Particularly suitable is polyethylene glycol (15) glyceryl monostearat which is commercially available, e.g. under the trade name TGMS®-15, e.g. from Nikko Chemicals Co., Ltd.
- x) Sugar fatty acid esters of e.g. C₁₂-C₁₈ fatty acids, e.g. sucrose monolaurate, e.g. Ryoto L-1695® as known and commercially available from e.g. Mitsubishi-Kasei Food Corp., Tokyo, Japan.
- xi) PEG sterol ethers having, e.g. from 5 to 35 [CH₂-CH₂-O] units, e.g. 20 to 30 units., e.g. Solulan® C24, as known and commercially available from e.g. Amerchol.
- xii) Salts of, e.g. C₈-C₁₈, fatty acids, -fatty acid sulfates and sulfonates, as known and commercially available from e.g. Fluka.
- xiii) Salts of, e.g. C₈-C₁₈, acylated amino acids, e.g. sodium lauroyl sarcosinate, as known and commercially available from e.g. Fluka.

xiv) Medium or long-chain alkyl, e.g. C₆-C₁₈, ammonium salts, e.g. cetyl trimethyl ammonium bromide, as known and commercially available from e.g. E. Merck AG.

5 It is to be appreciated that surfactants may be complex mixtures containing side products or unreacted starting products involved in the preparation thereof, e.g. surfactants made by polyoxyethylation may contain another side product, e.g. polyethylene glycol.

10 A surfactant having a hydrophilic-lipophilic balance (HLB) value of 8 to 17 is preferred. The surfactant selected preferably has a hydrophilic-lipophilic balance (HLB) of at least 10, for example Cremophor. The HLB value is preferably the mean HLB value.

15 In one aspect the present invention provides a composition according to the present invention wherein the surfactant is a reaction product of natural or hydrogenated vegetable oil and ethylene oxide, or sodium lauryl sulfate, preferably sodium lauryl sulfate.

In the pharmaceutical composition of the present invention, in a further alternative aspect the constitutional ratio of the surfactant : drug, e.g. cyclosporin, may be from about 0.6 – 80, e.g. 1 – 80, : 1 and preferably from about 1.5 to 25 : 1, on the basis of weight.

20 Preferably the composition on dilution with an aqueous medium, for example water, for example on dilution of 1:1 to 1:300, e.g. 1:1 to 1:70, e.g. 1:10 to 1:70, e.g. 1:10, or in the gastric juices after oral application, spontaneously forms an o/w (oil-in-water) emulsion, e.g. microemulsion.

25 A microemulsion is thermodynamically stable and contains dispersed particles of a mean size less than about 200 nm. Generally microemulsions comprise droplets or particles having a mean diameter of less than about 150 nm; typically less than 100 nm, generally greater than 10 nm, and stable over periods in excess of 24 hours. A "microemulsion" may be a non-opaque or substantially non-opaque, alternatively it may be a translucent colloidal
30 dispersion that is formed spontaneously or substantially spontaneously when its components are brought into contact. Further characteristics can be found in the above mentioned British patent application 2 222 770, the disclosure of which is incorporated herein by reference.

In one aspect the present invention provides a composition according to the present invention, the relative proportion of the poorly water soluble drug, e.g. cyclosporine or macrolide, the solubilizing component, and the surfactant in said composition being such that upon dilution with water, for example in a ratio of 1:1 to 1:300, e.g. 1:1 to 1:70, e.g. 1:10 to 1:70, e.g. 1:10, an oil-in-water microemulsion having particles of a mean size of less than 200 nm, is spontaneously formed.

Preferably, after dilution of the composition in an aqueous medium, the relative proportion of the solubilizing component and the surfactant lie within the "microemulsion" region on a standard three way plot. The compositions thus obtained are of high stability that are capable, on addition to an aqueous medium, of providing microemulsions having a mean particle size of < 200 nm.

Standard three way plots, e.g. phase diagrams, can be generated in a conventional manner as described in e.g. GB patent publication no. 2 222 770 or WO 96/13273.

In a further aspect of the present invention, after dilution with an aqueous medium a particulate system, e.g. of solid particles of the drug, e.g. of a size of from 50 nm to 2000 nm, is formed, e.g. in addition to the emulsion or microemulsion as described above.

The drug may be present in an amount by weight of up to about 35 % by weight of the composition. The drug is preferably present in an amount of 1 to 25 % by weight of the composition, for example about 2 to 20 %.

In one aspect the present invention provides a composition according to the present invention comprising the cyclosporine or macrolide in an amount of 1 to 35% by weight of the composition.

In a further alternative aspect the solubilizing, e.g. lipophilic component, may comprise 10 to 75 %, e.g. 10 to 50 %, by weight of the total weight of the composition, e.g. 15 to 45 %; preferably 20 to 40 % by weight of the composition.

In a further alternative aspect the surfactant may comprise 20 to 90 % by weight of the total weight of the composition, preferably 30 to 80 % by weight, more preferably 40 to 70 % by weight of the composition.

- 5 In one aspect the present invention provides a composition according to the present invention comprising the solubilizing, e.g. lipophilic component, in an amount of 10 to 75 %, e.g. 10 to 50 %, and the surfactant in an amount of 20 to 90 % by weight of the total weight of the composition.
- 10 Another substance which may be present is a carrier, e.g. a solid carrier. Suitable carriers for use according to the present invention, e.g. to obtain compositions in solid form, e.g. powder form, are, e.g. polymers, e.g. water soluble polymers, e.g. polyethylene glycol or polyvinylpyrrolidone, maltodextrin, e.g. Glucidex®, gummi arabicum, or gelatine; or water insoluble polymers, e.g. microcrystalline cellulose and derivatives thereof, or colloidal silica,
- 15 e.g. Aerosil®; or lactose; or dibasic anhydrous calcium phosphate, e.g. Fujicalin®.

In one aspect the present invention provides a composition according to the present invention wherein a carrier, e.g. a polymer, e.g. maltodextrin, gummi arabicum, or gelatine, or lactose is additionally present.

20

In the pharmaceutical composition according to the present invention, in a further alternative aspect the ratio of drug and solubilizing component : carrier is preferably in the range of 1 : 0.5 – 5, e.g. 1 : 1 - 5, more preferably 1 : 1 - 2 on the basis of weight.

- 25 In a further alternative aspect the present invention provides a composition according to the present invention wherein the solubilizing component and the drug are encapsulated in a polymeric matrix, e.g. according to a process comprising the following steps: (i) dissolving the drug in the solubilizing, e.g. lipophilic, component; (ii) mixing the solution obtained by step (i) with a solution of a polymer in a suitable, e.g. organic, solvent; (iii) delivering the
- 30 monophasic system containing the polymer, the solubilizing, e.g. lipophilic, component and the drug to a mixer together with e.g. a buffered gelatin solution to form e.g. an o/w emulsion; (iv) hardening the microparticles by solvent evaporation, washing for excipients removal and receiving the microparticles. In order to e.g. increase flowability of the final microparticle powder, the obtained microparticles may be further worked up by adding an

aqueous solution of a carrier, e.g. lactose, and lyophilization of the resulting suspension to obtain a flowable powder.

Accordingly, in one aspect the present invention provides a composition of the invention
5 wherein the drug dissolved in the solubilizing component is encapsulated in a polymeric matrix.

According to the present invention the polymeric matrix may comprise e.g. a water soluble polymer, e.g. polyethylene glycol or polyvinylpyrrolidone, or a water insoluble polymer, e.g.
10 d,l-poly(lactide-co-glycolide), especially d,l-poly(lactide-co-glycolide)/glucose. In a further alternative aspect of the present invention, e.g. to control drug release kinetics, mixtures of polymers, e.g. of a water insoluble polymer, e.g. d,l-poly(lactide-co-glycolide), e.g. d,l-poly(lactide-co-glycolide)/glucose, and a water soluble polymer, e.g. polyethylene glycol, or polyvinylpyrrolidone, or a polymer of dimethylaminoethylmethacrylates and methacrylic acid
15 esters, e.g. Eudragit® E, may be used.

The polymer used to encapsulate the drug together with the solubilizing component may be present in an amount of from 20 to 80 %, e.g. 40 to 50 %, by weight of the total weight of the microparticles comprising e.g. drug, solubilizing component and polymer.

20

In a further alternative aspect the invention also provides a process for the production of a pharmaceutical composition as defined above, e.g. in solid form, e.g. powder form, which process may comprise (i) dissolving the drug in the solubilizing component; (ii) encapsulating the solution obtained by step (i) in a polymeric matrix; (iii) spray drying or
25 freeze drying the microparticles obtained by step (ii), optionally together with a suitable carrier, to obtain e.g. a powder; (iv) admixing the composition, e.g. powder, obtained by step (iii) with the surfactant.

In a further alternative aspect the present invention provides a composition of the invention
30 which is in freeze-dried form.

Typically, when the compositions of the invention are formulated according to the process described above, the weight ratio of the sum of (i) drug, e.g. cyclosporin or macrolide, (ii) solubilizing component, and (iii) polymer : (iv) carrier may be from (i, ii, and iii) 1 : (iv) 0.1 - 2.

The surfactant may be present in an amount of from 5 to 60 %, e.g. 10 to 55 %, e.g. 50 %, by weight of the total weight of the composition comprising e.g. drug, solubilizing component, polymer, carrier and surfactant.

5

In yet a further alternative aspect the invention also provides a process for the production of a pharmaceutical composition as defined above, e.g. in solid form, e.g. powder form, which process may comprise (i) dissolving the surfactant in an aqueous solution, (ii) dissolving the drug in the solubilizing component, e.g. lipophilic component, (iii) mixing the aqueous solution of the surfactant with the drug solubilized in the lipophilic component, and (iv) spray-drying the mixture together with a suitable carrier in a conventional manner.

10

Accordingly, in one aspect the present invention provides a composition of the invention which is in spray-dried form.

15

Typically, when the compositions of the invention are formulated according to the process described above, the weight ratio of the sum of (i) drug, e.g. cyclosporin or macrolide, (ii) solubilizing component, and (iii) surfactant : (iv) carrier may be from (i, ii, and iii) 1 - 3 : (iv) 0.25 - 4.

20

The compositions, e.g. those in the examples hereinafter, show good stability characteristics as indicated by standard stability trials, for example having a shelf life stability of up to one, two or three years, and even longer. The compositions of this invention may produce stable emulsions or microemulsions and/or particulate systems, e.g. for up to one day or longer, e.g. one day.

25

The pharmaceutical composition may also include further additives or ingredients, for example antioxidants, such as ascorbyl palmitate, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tocopherols, and/or preserving agents. In a further alternative aspect these additives or ingredients may comprise about 0.05 to 1 % by weight of the total weight of the composition. The pharmaceutical composition may also include sweetening or flavoring agents in an amount of up to about 2.5 or 5% by weight based on the total weight of the composition. Preferably the antioxidant is α -tocopherol (vitamin E).

30

Details of excipients of the invention are described in e.g. Fiedler, H. P., loc cit; "Handbook of Pharmaceutical Excipients", loc cit; or may be obtained from the relevant manufacturers, the contents of which are hereby incorporated by reference.

- 5 Any carbon chain not otherwise specified herein conveniently contains 1 to 18 carbon atoms, e.g. 10 to 18 carbon atoms, when a terminal group or 2 or 3 carbon atoms when a polymer moiety.

It will be appreciated that the present invention encompasses

- 10 a) in respect of component (2) any of components i) to xiii) individually or in combination with one, two or more of the other components i) to xiii),
b) in respect of component (3) any of the surfactants specified above, e.g. surfactants i) to xiv), individually or in combination.

- 15 When required, the composition of the invention may be compounded into unit dosage form, for example filling the composition into gelatine capsules, e.g. hard gelatine capsules. Alternatively, the powder composition may be compressed into tablets in a conventional manner.

- 20 The composition of the invention may be combined with water or an aqueous solvent medium such that an emulsion, e.g. microemulsion, and/or a particulate system, is obtained. The emulsion, e.g. microemulsion, and/or particulate system, may be administered enterally, e.g. orally, e.g. as a capsule, e.g. soft gelatine capsule, or parenterally, e.g. as an infusion concentrate. Oral administration is preferred.

25

The compositions of the invention in solid form, e.g. powder form, e.g. spray-dried or freeze-dried form, are particularly suitable for the formulation of solid oral dosage forms, e.g. hard gelatine capsules or tablets.

- 30 It has also been found that stable compositions containing macrolides may be obtained by formulating the macrolide in an acidic environment. Compositions are understood herein to be stable when the macrolide drug substance remains substantially intact after a period of days or weeks at room temperature (25°C).

The acid may be lipid soluble and/or ethanol soluble. The acid may be for example a fatty acid, e.g. oleic acid. The acid may be a carboxylic acid, for example a mono-, di- or tri-carboxylic acid, and preferably a mono- or dicarboxylic acid. The acid may comprise one or more hydrophilic groups, e.g. hydroxy groups, and preferably one or two hydrophilic groups.

5 Suitable acids for use in this invention include malonic acid, fumaric acid, maleic acid, D-malic acid, L-malic acid, citric acid, ascorbic acid, succinic acid, oxalic acid, benzoic acid or lactic acid or an acid with a similar pKa, e.g. 2-7. Preferred acids include malonic acid, oxalic acid, citric acid and lactic acid. Malonic acid is more preferred.

10 The preferred amount of acid may be determined by routine experimentation. The ratio by weight of macrolide to acid in the compositions of this invention may be up to 20:1, for example from 1:5 to 5:1, e.g. 1:1. In a further alternative aspect the acid may be present in an amount of between 0.05% and 5% by weight of the composition.

15 In a further alternative aspect the macrolide may be present in an amount of 1 to 15 % by weight of the composition.

The macrolide may, for example, be formulated into a composition according to the present invention as defined above, and combined with an amount of acid. The acid-stabilised
20 composition may be administered enterally, e.g orally, e.g. as a capsule or drink solution, or parenterally, e.g. as an infusion concentrate. Oral administration is preferred.

The pharmaceutical compositions of the invention exhibit especially advantageous properties when administered orally; for example in terms of consistency and high level of
25 bioavailability obtained in standard bioavailability trials. These trials are performed in animals e.g. rats or dogs or healthy volunteers using HPLC or a specific or nonspecific monoclonal kit to determine the level of the drug substance, e.g. cyclosporin macrolide in the blood. For example, the composition of Example 1 administered p.o. to dogs may give surprisingly high C_{max} values as detected by ELISA using a specific monoclonal antibody.

30

In one aspect the present invention provides a method of orally administering a pharmaceutical composition, said method comprising orally administering to a patient in need of cyclosporin or macrolide therapy a composition according to the present invention.

Pharmacokinetic parameters, for example absorption and blood levels, also become surprisingly more predictable and problems in administration with erratic absorption may be eliminated or reduced. Additionally the pharmaceutical compositions are effective with biosurfactants or tenside materials, for example bile salts, being present in the gastro-intestinal tract. That is, the pharmaceutical compositions of the present invention are fully dispersible in aqueous systems comprising such natural tensides and thus capable of providing emulsion or microemulsion systems and/or particulate systems in situ which are stable. The function of the pharmaceutical compositions upon oral administration remain substantially independent of and/or unimpaired by the relative presence or absence of bile salts at any particular time or for any given individual.

The compositions of this invention reduce variability in inter- and intra-patient dose response.

In one aspect the present invention provides a method of reducing the variability of bioavailability levels of a cyclosporin or macrolide for patients during cyclosporin or macrolide therapy, said method comprising orally administering an oral pharmaceutical composition according to the present invention.

The utility of all the pharmaceutical compositions of the present invention may be observed in standard clinical tests in, for example, known indications of drug dosages giving equivalent blood levels of drug; for example using dosages in the range of 2.5 mg to 1000 mg of drug per day for a 75 kilogram mammal, e.g. adult and in standard animal models. The increased bioavailability of the drug provided by the compositions may be observed in standard animal tests and in clinical trials, e.g. as described above.

The optimal dosage of drug to be administered to a particular patient may be considered carefully as individual response to and metabolism of the drug, e.g. cyclosporin or macrolide, may vary, e.g. by monitoring the blood serum levels of the drug by radioimmunoassay, monoclonal antibody assay, or other appropriate conventional means. Dosages of the e.g. macrolide will generally range from 1 to 1000 mg per day, e.g. 2.5 mg to 1000 mg per day for a 75 kilogram adult, preferably 25 mg to 500 mg, with the optimal dosage being approximately 50 to 100 mg per day. Satisfactory results are obtained by administering about 75 mg per day for example in the form of two capsules, one containing

- 25 -

50 mg and one containing 25 mg; or three capsules each containing 25 mg. Cyclosporin dosages may be 25 to 1000 mg per day (preferably 50 mg to 500 mg) and the FK 506 dosage may be 1 mg to 1000 mg, e.g. 2.5 to 1000 mg, per day (preferably 10 mg to 250 mg). A daily dosage of between 0.01 and 5 mg/kg body weight/day, e.g. 0.5 and 5 mg/kg body weight/day, is indicated for administration of 40-0-(2-hydroxy)ethyl rapamycin.

10 The pharmaceutical compositions are preferably compounded in unit dosage form, for example by filling them into orally administrable capsule shells. The capsule shells may be soft or hard gelatine capsule shells, preferably hard gelatine capsule shells. Where the pharmaceutical composition is in unit dosage form, each unit dosage will suitably contain between 10 and 100 mg of the drug, more preferably between 10 and 50 mg; for example 15, 20, 25, or 50 mg. Such unit dosage forms are suitable for administration 1 to 5 times daily depending upon the particular purpose of therapy, the phase of therapy and the like.

15 However, if desired, the pharmaceutical compositions of the invention may be in drink solution form upon dilution with water or any other aqueous system, to provide emulsion, e.g. microemulsion, and/or particulate systems suitable for drinking.

20 The pharmaceutical compositions of the invention are useful for the same indications as the poorly water soluble drugs. The pharmaceutical compositions are particularly useful for treatment and prevention of the conditions disclosed at pages 40 and 41 in EP 427 680, and at pages 5 and 6 in PCT/EP93/02604, the contents of which applications are incorporated herein by reference.

25 The pharmaceutical compositions comprising e.g. an immunosuppressant, e.g. cyclosporin, as pharmacologically active agent, are particularly useful for:

30 a) treatment and prevention of organ or tissue transplant rejection, for example for the treatment of the recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. The pharmaceutical compositions are also indicated for the prevention of graft-versus-host disease, such as sometimes occurs following bone marrow transplantation;

b) treatment and prevention of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component

such as arthritis (for example rheumatoid arthritis, arthritis chronic progrediente and arthritis deformans) and rheumatic diseases; and

c) treatment of multi-drug resistance (MDR).

5

In a further aspect the present invention provides the use of a composition according to the present invention in the manufacture of a medicament for the treatment and prevention of an autoimmune or inflammatory condition or for the treatment and prevention of transplant rejection or for the treatment of multi-drug resistance.

10

The macrolide drugs also exhibit anti-tumour and antifungal activity and hence the pharmaceutical compositions can be used as anti-tumour and anti-fungal agents.

The contents of all the references referred to above especially the exemplified compounds are incorporated herein by reference, and each of the exemplified compounds may be used as a macrolide in the examples listed below.

15

Examples

Following is a description by way of example only of compositions of this invention.

Unless otherwise indicated, components are shown in % by weight based on each composition.

20

Solubilizing components:

Sunfat® GDC-N is from Taiyo Kagaku Co., Japan.

25

Oleyl alcohol from Henkel, Germany

Lauroglycol 90® from Gattefossé, France

Capryol 90® from Gattefossé, France

Sefsol 218® from Nikkol, Japan

Surfactants:

30 Cremophor® RH 40 is from BASF, Germany.

SDS (Texapon K12®) from Fluka, Switzerland and Henkel, Germany

Solutol HS15® from BASF, Germany

Myrj 52® from Uniqema, Great Britain

Pluronic F68® from BASF, Germany

Brij 35® from Uniqema, Great Britain

Particle size measurements are made at 20°C at a dilution of 1 g composition in 10 to
 5 100 ml water by photon correlation spectroscopy using, for example a Brookhaven BI-
 200 SM from Brookhaven Instruments, and by microscopy using, for example a Zeiss
 DMLB microscope.

Example 1:

10 Preparation of compositions

Compositions are made up by (i) dissolving the surfactant in water, (ii) dissolving the
 drug in the solubilizing component, and (iii) mixing the aqueous solution of the surfactant
 with the solution obtained by step (ii).

Particle size is measured by a Zetasizer or a microscope.

15

COMPONENT	QUANTITY			
	I	II	III	IV
	%	%	%	%
(1) poorly soluble drug				
20 Cyclosporin A	7.7	12.5	9.7	7.9
(2) solubilizing component				
Oleyl alcohol	30.8	29.2	22.6	18.4
(3) surfactant				
25 Sodium Lauryl Sulfate	61.5	58.3	67.7	73.7
ratio composition:water (g)	1.3+10	1.2+10	1.55+50	1.9+50
mean droplet size (nm)	88.5	45.5	51.5	86.6

30

COMPONENT	V	VI	VII	VIII	IX
	%	%	%	%	%
(1) poorly soluble drug					
35 Cyclosporin A	2.7	2.7	2.7	18.2	18.2
(2) solubilizing component					
Lauroglycol® 90	24.3	-	-	-	-
Sefsol® 218	-	24.3	-	-	-
Sunfat® GDC-N	-	-	24.3	-	27.3

- 28 -

5	Capryol® 90	-	-	-	27.3	-
	(3) surfactant					
	Sodium Lauryl Sulfate	73.0	73.0	73.0	-	-
	Cremophor® RH40	-	-	-	54.5	54.5
	ratio composition:water (g)	1.85+10	1.85+10	1.85+10	1.1+50	1.1+50
10	max droplet size (nm)	-	-	-	-	<12.5µm
		X	XI	XII	XIII	
		%	%	%	%	
	(1) poorly soluble drug					
	Cyclosporin A	18.2	18.2	18.2	18.2	
15	(2) solubilizing component					
	Lauroglycol® 90	27.3	-	-	-	
	Capryol® 90	-	-	27.3	-	
	Sunfat® GDC-N	-	27.3	-	27.3	
	(3) surfactant					
20	Solutol® HS15	54.5	54.5	-	-	
	Myrj® 52	-	-	54.5	54.5	
	ratio composition:water (g)	1.1+50	1.1+50	1.1+50	1.1+50	
	max droplet size (µm)	1.25	<20	<14	<20	
25		XIV	XV	XVI	XVII	
		%	%	%	%	
	(1) poorly soluble drug					
	Cyclosporin A	24.0	18.2	18.2	18.2	
	(2) solubilizing component					
30	Lauroglycol® 90	-	27.3	27.3	-	
	Capryol® 90	36.0	-	-	-	
	Sunfat® GDC-N	-	-	-	27.3	
	(3) surfactant					
	Pluronic® F68	40.0	54.5	-	-	
35	Brij® 35	-	-	54.5	54.5	
	ratio composition:water (g)	0.1+10	1.1+50	1.1+50	1.1+50	
	max droplet size (µm)	<7µm	<1.25	<45	<70	

- 29 -

	XVIII	XIX	XX	XXI
	%	%	%	%
5				
(1) poorly soluble drug				
Cyclosporin A	25.0	25.0	18.2	14.3
(2) solubilizing component				
Lauroglycol® 90	-	37.5	27.3	21.4
Capryol® 90	37.5	-	-	-
(3) surfactant				
10 Sodium Lauryl Sulfate	37.5	37.5	54.5	64.3
ratio composition:water (g)	1.4+50	1.4+50	1.1+50	0.8+50
max droplet size (µm)	<7.5	-	-	-
15				
	XXII	XXIII	XXIV	XXV
	%	%	%	%
20				
(1) poorly soluble drug				
Cyclosporin A	32.0	17.6	18.75	20.0
(2) solubilizing component				
Lauroglycol® 90	-	41.2	43.75	46.7
Capryol® 90	48.0	-	-	-
(3) surfactant				
25 Sodium Lauryl Sulfate	20.0	41.2	37.5	33.3
ratio composition:water (g)	0.1+10	1.7+10	0.16+10	0.15+10
mean droplet size (nm)	20µm ¹⁾	97.5	121.1	129.5
30 ¹⁾ max droplet size				

The compositions are spray-dried together with Glucidex® as a carrier in an amount of about 23 % by weight of the total composition consisting of drug, solubilizing component, surfactant and carrier, and encapsulated into hard gelatine capsules or compressed to tablets.

Further examples may be made replacing Cyclosporin A by any of the drugs specified above, e.g. 2 mg 40-O-(2-hydroxy)ethyl-rapamycin, or 30 mg 33-epi-chloro-33-desoxy-ascomycin.

Other examples may be made by replacing Oleyl alcohol, Lauroglycol®90, Capryol®90, Sefsol®218, Sunfat®GDC-N by any of the solubilizing components specified above.

Other examples may be made by replacing Sodium lauryl sulfate, Cremophor®RH40, Solutol®HS15, Myrj®52, Pluronic®F68, Brij®35 by any of the surfactants specified above.

5

The examples illustrate compositions useful for example in the prevention of transplant rejection or for the treatment of autoimmune disease, on administration of from 1 to 5 unit dosages/day at a dose of 2 to 5 mg/kg per day. The examples are described with particular reference to Cyclosporin A but equivalent compositions may be obtained employing any macrolide or other drug.

10

On visual inspection after dilution, each of the compositions forms a stable microemulsion or emulsion.

15

Claims

1. A pharmaceutical composition in solid form comprising
 - (i) a poorly water soluble drug,
 - 5 (ii) a solubilizing component,
 - (iii) a surfactant which is semisolid or solid at room temperature,
wherein the ratio of (iii) to (ii) is from 0.3 - 4 to 1, and
which on dilution with an aqueous medium forms an emulsion or a microemulsion
and/or a particulate system.
- 10 2. A composition according to claim 1 further comprising a carrier.
3. A composition according to claim 2 wherein the carrier is maltodextrin, lactose, gummi
arabicum or gelatine.
- 15 4. A composition according to any preceding claim wherein the drug is Cyclosporin A.
5. A composition according to any preceding claim wherein the surfactant is
polyethoxylated hydrogenated castor oil, polyoxyethylene fatty acid ester,
20 polyoxyethylene-polyoxypropylene co-polymer, polyoxyethylene alkyl ether, or sodium
lauryl sulfate.
6. A composition according to any preceding claim wherein the solubilizing component is
a glyceryl mono- or di fatty acid ester, a propylene glycol mono- or di- fatty acid ester,
25 or a fatty alcohol.
7. A composition according to any preceding claim wherein the drug dissolved in the
solubilizing component is encapsulated in a polymeric matrix.
- 30 8. A composition according to any preceding claim in spray-dried form.
9. A process for the production of a composition according to claim 7 or 8 which process
comprises
 - (i) dissolving the drug in the solubilizing component,

- (ii) encapsulating the solution obtained by step (i) in a polymeric matrix,
- (iii) spray drying or freeze drying the microparticles, optionally together with a carrier, to obtain a powder,
- (iv) admixing the powder obtained by step (iii) with the surfactant.

5

10. A process for the production of a composition according to claim 8 which process comprises

- (i) dissolving the surfactant in an aqueous solution,
- (ii) dissolving the drug in the solubilizing component,
- (iii) mixing the solution obtained by step (i) with the solution obtained by step (ii), and
- (iv) spray-drying the mixture together with a carrier.

10

11. A composition obtainable by a process as claimed in claim 9 or 10 further worked up in the form of tablets or capsules.

15

12. A composition according to any one of claims 1 to 8 in form of a oral solid dosage form.

20

13. Use of a composition as claimed in any one of claims 1 to 8, 11 or 12 in the manufacture of a medicament for the treatment of autoimmune diseases or for the use as an immunosuppressant.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/76561 A3

- (51) International Patent Classification⁷: **A61K 9/16**,
9/107, 38/13 Steinbrunn-le-Haut (FR), **MARCHAL, Laurent** [FR/FR];
22, Rue Ernest-Bichat, F-54000 Nancy (FR).
- (21) International Application Number: PCT/EP01/04051 (74) Agent: **BECKER, Konrad**; Novartis AG, Corporate
Intellectual Property, Patent & Trademark Department,
CH-4002 Basel (CH).
- (22) International Filing Date: 9 April 2001 (09.04.2001)
- (25) Filing Language: English (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (26) Publication Language: English
- (30) Priority Data:
0008785.8 10 April 2000 (10.04.2000) GB (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except AT, US*): **NO-**
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).
- (71) Applicant (*for AT only*): **NOVARTIS-ERFINDUNGEN**
VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT];
Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **AMBÜHL,**
Michael [CH/CH]; Bahnhofstrasse 93a, CH-4313 Möhlin
(CH). **HAEBERLIN, Barbara** [CH/CH]; Haselrain 77,
CH-4125 Riehen (CH). **LÜCKEL, Barbara** [DE/DE];
Pestalozzistrasse 22, 79540 Lörrach (DE). **MEINZER,**
Armin [DE/DE]; Fliederweg 2, 79426 Buggingen (DE).
LAMBERT, Olivier [FR/FR]; Rue des Bergers 6, F-68440
- Published:
- - with international search report
- (88) Date of publication of the international search report:
21 February 2002
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention provides a pharmaceutical composition in solid form comprising a poorly water soluble drug, a solubilizing component, and a surfactant which is semisolid or solid. The poorly soluble drug may e.g. be a cyclosporine or a macrolide.

WO 01/76561 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/04051

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/16 A61K9/107 A61K38/13

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 198 19 273 A (PHARMATEC INTERNATIONAL) 11 November 1999 (1999-11-11) page 3, line 42 - line 48 page 5, line 30 - line 34 examples 1,7,8	1,2,4-6, 8,10-13
X	PEDERSEN G P ET AL: "Solid state characterisation of a dry emulsion: A potential drug delivery system." INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 171, no. 2, pages 257-270, XP001029905 ISSN: 0378-5173 abstract paragraphs '02.1!-'02.3!; table 1 paragraphs '03.1!', '04.3! ----- -/-	1-3,6-8, 10-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

22 October 2001

Date of mailing of the international search report

02/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/EP 01/04051

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 27946 A (CHONG KUN DANG CORP) 10 June 1999 (1999-06-10) page 4, line 22 -page 6, line 16 page 7, line 6 - line 8 examples 1-4,8-11,15-18 ---	1,2,4-8, 11-13
X	WO 95 32726 A (YUHAN CORP) 7 December 1995 (1995-12-07) page 3, line 16 - line 32 page 4, line 1 - line 25 example 1 ---	1,2,4,5, 7,8,12, 13
X	WO 00 00179 A (WON JIN BIOPHARMA CO LTD) 6 January 2000 (2000-01-06) example 20 ---	1,2,4-7, 12,13
X	EP 0 556 394 A (NIPPON SHINYAKU CO LTD) 25 August 1993 (1993-08-25) example 5 ---	1,2,4, 12,13
X	EP 0 327 280 A (SANKYO CO) 9 August 1989 (1989-08-09) page 5, line 13 - line 22 example 1 ---	1,4-6,8, 12,13
A	WO 99 13900 A (SHERMAN BERNARD CHARLES) 25 March 1999 (1999-03-25) page 5, line 8 - line 31 examples -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/04051

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19819273	A	11-11-1999	DE 19819273 A1	11-11-1999
			AU 4035199 A	23-11-1999
			WO 9956733 A1	11-11-1999
			EP 1073426 A1	07-02-2001
WO 9927946	A	10-06-1999	AU 1508899 A	16-06-1999
			WO 9927946 A1	10-06-1999
WO 9532726	A	07-12-1995	AT 183398 T	15-09-1999
			AU 2577295 A	21-12-1995
			CN 1149834 A	14-05-1997
			DE 69511539 D1	23-09-1999
			DE 69511539 T2	30-03-2000
			DK 756489 T3	06-12-1999
			EP 0756489 A1	05-02-1997
			ES 2137516 T3	16-12-1999
			GR 3031568 T3	31-01-2000
			JP 2936209 B2	23-08-1999
			JP 9510733 T	28-10-1997
			WO 9532726 A1	07-12-1995
			KR 163212 B1	01-12-1998
			RU 2119351 C1	27-09-1998
			US 5739105 A	14-04-1998
WO 0000179	A	06-01-2000	AU 4655699 A	17-01-2000
			WO 0000179 A1	06-01-2000
EP 0556394	A	25-08-1993	AU 665931 B2	25-01-1996
			AU 8766791 A	26-05-1992
			CA 2095627 A1	07-05-1992
			EP 0556392 A1	25-08-1993
			EP 0556394 A1	25-08-1993
			HU 64864 A2	28-03-1994
			WO 9207571 A1	14-05-1992
			WO 9207552 A1	14-05-1992
			WO 9207551 A1	14-05-1992
			JP 2653246 B2	17-09-1997
			JP 2626247 B2	02-07-1997
			JP 2616240 B2	04-06-1997
			KR 154343 B1	16-11-1998
			RU 2097025 C1	27-11-1997
			US 5635491 A	03-06-1997
			US 5534502 A	09-07-1996
EP 0327280	A	09-08-1989	AT 73676 T	15-04-1992
			AU 2885389 A	03-08-1989
			CA 1326995 A1	15-02-1994
			DE 68900991 D1	23-04-1992
			EP 0327280 A1	09-08-1989
			ES 2033086 T3	01-03-1993
			GR 3004611 T3	28-04-1993
			HK 35697 A	27-03-1997
			JP 2049733 A	20-02-1990
			JP 2632010 B2	16-07-1997
			US 4990337 A	05-02-1991
WO 9913900	A	25-03-1999	NZ 328751 A	28-01-1999
			AU 9149198 A	05-04-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/04051

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9913900	A	BR 9806212 A	18-04-2000
		WO 9913900 A1	25-03-1999
		CN 1239432 T	22-12-1999
		CZ 9901570 A3	15-09-1999
		EP 0957931 A1	24-11-1999
		HU 0000839 A2	28-11-2000
		JP 2001505928 T	08-05-2001
		NO 992340 A	06-07-1999
		PL 333353 A1	06-12-1999
		SI 9820010 A	31-08-1999
		TR 9901070 T1	22-11-1999
		US 6197335 B1	06-03-2001
		ZA 9808452 A	30-03-1999